Table of Contents
Clinical Trials in Patients with Resected Stage IIB and III Melanoma
Risk of opening trials to those who refuse IFN
The process of informed consent
Proposal for phase II trials in patients eligible for HD-IFN?.
Benefits of system for informed consent
Alternate recommendation: Shorten wait after refusal of IFN
Author: Craig Slingluff